ClinicalTrials.gg
CompletedNCT01046864Updated Sep 16, 2014

Combination of Brivanib With 5-Fluorouracil/Leucovorin (5FU/LV) and 5-Fluorouracil/Leucovorin/Irinotecan (FOLFIRI)

A Phase 1 interventional study of 5-FU and Leucovorin in Gastro-Intestinal Cancer, sponsored by Bristol-Myers Squibb. Completed at 6 sites in 3 countries. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-09-16.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
49
Allocation
Non-randomized
Ages
20 Years to 75 Years
Sex
All
01

Study summary

The purpose of this study is to determine a safe and maximum tolerable dose of Brivanib when combined with standard dose 5FU/LV and FOLFIRI.

02

Conditions studied

  • Gastro-Intestinal Cancer

Keywords

  • Gastro-Intestinal Cancer, NOS
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion criteria

Inclusion Criteria:

  • Histological/cytological confirmed diagnosis of Gastrointestinal , except pancreatic cancer
  • Eligible for 5FU/LV or FOLFIRI chemotherapy
  • 0-1
  • Able to swallow and tolerate tablets
  • of 3 months

Exclusion criteria

Exclusion Criteria:

  • Unwilling to use acceptable method to avoid pregnancy of partner/self for the entire study period and up to 4 weeks after last dose
  • Women who are pregnant or breastfeeding
  • Pancreatic cancer
  • Known , evidence of
  • History of thrombo-embolic disease
  • Hemorrhage/bleeding events
  • Uncontrolled or significant cardiovascular disease
  • Any 3 or more of the following risk factors: arterial thrombosis , smoking, hypercholesterolemia, hypertension, obesity (BMS>30) and diabetes
  • Pre-existing thyroid abnormality, not maintained with medication
  • QTC (Fridericia) >450 msec on two consecutive 's
  • Subjects with concomitant second ( except adequately treated non-melanoma skin, in situ carcinoma of bladder, cervix or breast, early prostate cancer)
  • Any major surgery within 4 weeks of study drug administration
  • Increased levels of both D-Dimer and Prothrombin fragment 1 +2
  • Arm B and C only-positive UGT1A1 genotype of TA7/TA7
  • History of allergy of brivanib or drug class
  • History of severe reactions to fluoropyrimidine therapy or irinotecan
  • Prior therapy with brivanib
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Factorial assignment
Masking
None (open label)
Enrollment
49 participants (actual)

Study arms

  • Experimental
    Arm 1

    Drug: 5-FU · Drug: Leucovorin · Drug: Brivanib

  • Experimental
    Arm 2

    Drug: 5-FU · Drug: Leucovorin · Drug: Irinotecan · Drug: Brivanib

  • Experimental
    Arm 3

    Japanese Population

    Drug: 5-FU · Drug: Leucovorin · Drug: Irinotecan · Drug: Brivanib

Interventions

  • Drug5-FU

    IV solution, IV bolus over 2-4 minutes, 400 mg/m², Every 14 days, Until disease progression/toxicity

    Also known as: Fluorouracil

  • IV solution, IV over 2 hours, 400 mg/m², Every 14 days, Until disease progression/toxicity

    Also known as: Folinic acid

  • Drug5-FU

    IV solution, IV infusion over 46 hours, 2400 mg/m², Every 14 days, Until disease progression/toxicity

    Also known as: Fluorouracil

  • IV solution, IV over 90 minutes, 180 mg/m², Every 14 days, Until disease progression/toxicity

    Also known as: Camptosar

  • Tablets, Oral, 400 - 800 mg, once daily, Until disease progression/toxicity

  • Tablets, Oral, 600 - 800 mg, once daily, Until disease progression/toxicity

    Also known as: BMS-582664

  • Tablets, Oral, 800 mg, once daily, Until disease progression/toxicity

    Also known as: BMS-582664

06

What researchers measure

Primary outcomes

  1. Safety-Toxicity, evaluated according to NCI Common Terminology Criteria for Adverse Events v3.0. Assessments based on medical review of adverse events, results of vital signs, ECGs, echocardiography, physical examinations, and clinical laboratory tests

    Time frame: Cycle 4, Day 1

Secondary outcomes

  1. Pharmacokinetics (Cmax, Tmax, AUC (TAU), T-HALF) plasma concentration vs time for brivanib given alone and in combination with FOLFIRI. Individual concentrations (C) of 5FU will be calculated from samples on Day 2 in the presence and absence of Brivanib

    Time frame: Cycle 2, Day 2

  2. Efficacy-Tumor BOR determined for treated subjects by radiological responses assessed by CT scan or MRI, by RECIST criteria (v1.1). Radiological tumor assessments to evaluate response & progression will be done every 8 wks or more frequently if indicated

    Time frame: Every 8 weeks

  3. Exploratory Measures (Biomarkers for Predictive Analysis): Potential predictive markers, including activity of FGF, VEGF and related pathways as well as K-RAS mutation status, will be evaluated based on blood or tumor samples

    Time frame: Cycle 1, Cycle 2, every other cycle

07

Study locations

6 sites
  • Usc/Norris Comprehensive Cancer Center
    Los Angeles, California 90033, United States
  • Texas Oncology
    Dallas, Texas 75246, United States
  • Scott & White Memorial Hospital And Clinic
    Temple, Texas 76508, United States
  • Local Institution
    Edmonton, Alberta T6G 1Z2, Canada
  • Local Institution
    Ottawa, Ontario K1H 8L6, Canada
  • Local Institution
    Villejuif Cedex, 94800, France
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2010, a primary completion of Jun 2014 and a completion of Jun 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2010
First posted
Jan 12, 2010
Start
Feb 2010
Primary completionActual
Jun 2014
CompletionActual
Jun 2014
Last update
Sep 16, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01046864
Responsible party
Sponsor
First posted
Jan 12, 2010
Start date
Feb 2010
Primary completion
Jun 2014
Completion
Jun 2014
Last update
Sep 16, 2014

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fluorouracil · Leucovorin · Brivanib

Start the discussion